Steven J Podd1, Nicholas Freemantle2, Stephen S Furniss1, Neil Sulke3. 1. Cardiology Research Department, East Sussex Healthcare NHS Trust, Eastbourne District General Hospital, Kings Drive, Eastbourne, East Sussex BN21 2UD, UK. 2. Department of Primary Care and Population Health, PRIMENT Clinical Trials Unit, UCL Medical School, London, UK. 3. Cardiology Research Department, East Sussex Healthcare NHS Trust, Eastbourne District General Hospital, Kings Drive, Eastbourne, East Sussex BN21 2UD, UK neil.sulke@esht.nhs.uk.
Abstract
AIMS: To assess the efficacy of BMS 914392 on atrial fibrillation (AF) burden reduction in 20 patients with pacemakers and paroxysmal atrial fibrillation (PAF). BMS 914392 is a potent, selective, oral inhibitor of the IKACh current and has been shown to suppress AF, whilst having no effect on the ventricular refractory period. This is the first efficacy study of BMS 914392 in patients with PAF. METHODS AND RESULTS: The study was a four-way, crossover, double-blind design. A total of 20 patients with PAF and dual-chamber pacemakers were recruited. The pacemakers allowed beat-to-beat monitoring. Anti-arrhythmic drugs were withdrawn. Patients received low-dose (10 mg OD), medium-dose (10 mg TDS), and high-dose (20 mg TDS) BMS 914392 or placebo for 3 weeks before being crossed to the next phase. Patients underwent a washout period, four treatment phases and a final washout phase. Atrial fibrillation burden was downloaded from their pacemakers at the end of each study phase. BMS 914392 did not reduce AF burden when compared with placebo (10 mg OD P = 0.56, 10 mg TDS P = 0.22, 20 mg TDS P = 0.23). Heart rate and corrected QT (QTc) were not affected by BMS 914392. Adverse event (AE) rates did not differ from placebo in any of the treatment groups, with no serious AEs recorded. CONCLUSION:BMS 914932 has not been shown to reduce AF burden in patients with PAF and pacemakers using beat-to-beat pacemaker monitoring throughout the study. BMS 914392 was well tolerated and did not affect QTc or reduce heart rate. TRIAL REGISTRATION: Clinicaltrials.gov: NCT01356914. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIMS: To assess the efficacy of BMS 914392 on atrial fibrillation (AF) burden reduction in 20 patients with pacemakers and paroxysmal atrial fibrillation (PAF). BMS 914392 is a potent, selective, oral inhibitor of the IKACh current and has been shown to suppress AF, whilst having no effect on the ventricular refractory period. This is the first efficacy study of BMS 914392 in patients with PAF. METHODS AND RESULTS: The study was a four-way, crossover, double-blind design. A total of 20 patients with PAF and dual-chamber pacemakers were recruited. The pacemakers allowed beat-to-beat monitoring. Anti-arrhythmic drugs were withdrawn. Patients received low-dose (10 mg OD), medium-dose (10 mg TDS), and high-dose (20 mg TDS) BMS 914392 or placebo for 3 weeks before being crossed to the next phase. Patients underwent a washout period, four treatment phases and a final washout phase. Atrial fibrillation burden was downloaded from their pacemakers at the end of each study phase. BMS 914392 did not reduce AF burden when compared with placebo (10 mg OD P = 0.56, 10 mg TDS P = 0.22, 20 mg TDS P = 0.23). Heart rate and corrected QT (QTc) were not affected by BMS 914392. Adverse event (AE) rates did not differ from placebo in any of the treatment groups, with no serious AEs recorded. CONCLUSION: BMS 914932 has not been shown to reduce AF burden in patients with PAF and pacemakers using beat-to-beat pacemaker monitoring throughout the study. BMS 914392 was well tolerated and did not affect QTc or reduce heart rate. TRIAL REGISTRATION: Clinicaltrials.gov: NCT01356914. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Yoshio Takemoto; Diana P Slough; Gretchen Meinke; Christopher Katnik; Zachary A Graziano; Bojjibabu Chidipi; Michelle Reiser; Mohammed M Alhadidy; Rafael Ramirez; Oscar Salvador-Montañés; Steven Ennis; Guadalupe Guerrero-Serna; Marian Haburcak; Carl Diehl; Javier Cuevas; Jose Jalife; Andrew Bohm; Yu-Shan Lin; Sami F Noujaim Journal: FASEB J Date: 2018-01-05 Impact factor: 5.191
Authors: Merle Friederike Fenner; Helena Carstensen; Sarah Dalgas Nissen; Eva Melis Hesselkilde; Christine Scott Lunddahl; Maja Adler Hess Jensen; Ameli Victoria Loft-Andersen; Stefan Michael Sattler; Pyotr Platonov; Said El-Haou; Claire Jackson; Raymond Tang; Robert Kirby; John Ford; Ulrich Schotten; James Milnes; Ulrik Svane Sørensen; Thomas Jespersen; Rikke Buhl Journal: Br J Pharmacol Date: 2020-06-24 Impact factor: 8.739
Authors: Allison Anderson; Baovi N Vo; Ezequiel Marron Fernandez de Velasco; Corey R Hopkins; C David Weaver; Kevin Wickman Journal: Mol Pharmacol Date: 2021-09-09 Impact factor: 4.436
Authors: Márcia Vagos; Ilsbeth G M van Herck; Joakim Sundnes; Hermenegild J Arevalo; Andrew G Edwards; Jussi T Koivumäki Journal: Front Physiol Date: 2018-09-04 Impact factor: 4.566